

Selected literature on Helixor® therapy for breast cancer

1. Auerbach L, Vaclavik-Fleck I, Dostal V, Kubista E. Significant higher level of activated NKcells in patients with breast cancer receiving a Viscum album (mistletoe) extract during chemotherapy. 11th Annual Symposium on Complementary Health Care, 17. - 19.11.2004, Focus on Alternative and Complementary Therapies 9[3/4]. 2004.
2. Auerbach L, Dostal V, Vaclavik-Fleck I, Kubista E, Rosenberger A, Rieger S, et al. Signifikant höherer Anteil aktivierter NK-Zellen durch additive Misteltherapie bei chemotherapierten Mamma-Ca-Patientinnen in einer prospektiv-randomisierten doppelblinden Studie. In: Scheer R et al., editors. Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC-Verlag; 2005. S. 543-54.
3. Beuth J, Schierholz J, Schneider B. Safety and efficacy of treatment of breast cancer patients with standardized mistletoe extract: A controlled multicenter comparative cohort study. *Phytomedicine* 2007;14(Suppl VII): 39.
4. Beuth J, Schierholz J, Schneider B. Mistelextrakt in der Nachsorge von Mammakarzinompatientinnen. *Erfahrungsheilkunde* 2008;57: 149-53.
5. Beuth J, Schierholz JM, Schneider B. Unbedenklichkeit und Wirksamkeit der Behandlung mit einem standardisierten Mistelextrakt in der Nachsorge von MammakarzinomPatientinnen - Eine retrospektive, kontrollierte, epidemiologische Kohortenstudie. [Safety and efficacy of complementary treatment of breast cancer patients with standardized mistletoe extract in the aftercare period - a retrospective, controlled epidemiological cohort study]. In: Scheer R et al., editors. *Die Mistel in der Tumorthherapie 2*. Essen: KVC Verlag; 2009. S. 577-86. Beuth J, Schneider B, Schierholz JM. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. *Anticancer Research* 2008;28(1B): 523-527.
6. Çetin ES, et al. The Viscum album L. extracts induce apoptosis of human breast cancer Mda-Mb-231 cells. *Cell Membranes and Free Radical Research* 2014;6(1):394. 49. Çetin ES et al. Conformation of apoptotic effect of the Viscum album L. extracts on human breast cancer MCF-7 cells with TUNEL assay. *Cell Membranes and Free Radical Research* 2015;6(1):408
7. Devi, S., et al. (2023). "Characterization of Viscum album L. Effect on Immune Escape Proteins PD-L1, PD-L2, and MHC-I in the Prostate, Colon, Lung, and Breast Cancer Cells." *Complementary Medicine Research* 30(5): 386-392.
8. Gritzko K, Krätzer F. Helixor® A, M and P: In vitro mammalian Chromosome Aberration Test. Martinsried: GenPharmTox Bio Tech AG; 2005. Report No.: 100096.

9. Gutsch J, Berger H, Scholz G, Denck H. Prospektive Studie beim radikal operierten Mammakarzinom mit Polychemotherapie, Helixor® und unbehandelter Kontrolle. Deutsche Zeitschrift für Onkologie 1988;20(4): 94-101.
10. Hellan J, Salzer G, Wutzlhofer F. Das operierte Mammakarzinom - Retrospektive Auswertung. In: Jungi WF et al., editors. Krebs und Alternativmedizin II. Berlin: Springer; 1990. S. 63-9.
11. Hollinsky C, Danmayr E. Prognose des kleinen Mammakarzinoms (T1 N0) - Retrospektive Analyse anhand von 516 Fällen. Deutsche Zeitschrift für Onkologie 1987;19(3): 77-83.
12. Jaenichen D, Schink M, Preussler C, Rieger S, Dehus O Influence of a Helixor P infusion therapy on the Cancer-related Fatigue (CrF) of patients with advanced breast cancer or NSCLC during oncological standard therapy. 2019 Phytomedicine 61 (S1).
13. Kechagioglou P, Fuller-Shavel N. Integrative Oncology in Breast Cancer Care. Springer Cham, 2024;1: 111-112.
14. Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. Journal of Experimental & Clinical Cancer Research 2009;28: 79.
15. Kowarschik S et al. Characterisation of Viscum album L. effect on immune escape proteins PD-L1, PD-L2 and MHC-I in prostate, colon, lung and breast cancer cells. Complementary Medicine Research 2023;30(5): 386-392.
16. Loef, M., Paepke, D., Wallach, H. Quality of life in breast cancer patients treated with mistletoe extracts: a systematic review and meta-analysis. Integrative Cancer Therapies 2023; 22: 1-11.
17. Mansky PJ, Grem J, Wallerstedt DB, Monahan BP, Blackman MR. Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy. Integrative Cancer Therapies 2003;2(4): 345-52.
18. Mansky PJ, Wallerstedt DB, Sannes T, Johnson L, Blackman MR, Grem JL, et al. NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. Journal of Clinical Oncology 2010;28(15 suppl): 2559.
19. Mansky PJ, Wallerstedt DB, Sannes T, Stagl J, Johnson L, Blackman MR, et al. NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. Phytomedicine 2011;18(Suppl.1): 12.
20. Mansky PJ, Wallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, et al. NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. Evidence-Based Complementary and Alternative Medicine 2013; Article ID 964592:11 pages.
21. Maris B. Ein erfreulich langer Verlauf – Fallgeschichte einer Frau mit Brustkrebs. Der Merkurstab 2017; Heft 5: 436-438.
22. Matthes H, Piao BK, Wang YX, Xie GR, Mansmann U, Beuth J, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and

nonsmall cell lung cancer patients. A prospective randomized controlled clinical trial. *Journal of Cancer Research and Clinical Oncology* 2004;130(Supplement 1): AS919.

23. Mazurakova A et al. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. *EPMA Journal* 2022;13(2): 315-334
24. Oei SL, Thronicke A, Kröz M, von Trott P, Schad F, Matthes H. Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients. *Integr Cancer Ther.* 2020;19: 1534735420917211.
25. Park YR et al. Viscum album Induces Apoptosis by Regulating STAT3 Signaling Pathway in Breast Cancer Cells." *International journal of molecular sciences* 2023;24(15): 11988.
26. Piao BK, Wang YX, Xie GR. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. (P)*Alternative Medicine Review* 2004;9(2): 219.
27. Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth JL. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. *Anticancer Research* 2004;24(1): 303-10.
28. Preisfeld A. Influence of aqueous mistletoe preparations on humoral immune parameters with emphasis on the cytotoxicity of human complement in breast cancer patients. *Forschende Komplementärmedizin und Klassische Naturheilkunde* 1997;4: 224-8.
29. Schad F, Thronicke A. Safety of Combined Targeted and Helixor® Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study." *International Journal of Environmental Research and Public Health* 2023;20(3): 2565.
30. Schnell-Inderst P et al. Additional treatment with mistletoe extracts for patients with breast cancer compared to conventional cancer therapy alone - efficacy and safety, costs and costeffectiveness, patients and social aspects, and ethical assessment. *German medical science: GMS e-journal* 2022;20.
31. Schöffski O, Emmert M. Vergleichende Kostenanalyse der Nachsorge beim Mammakarzinom unter besonderer Berücksichtigung von Mistelpräparaten. *Deutsche Zeitschrift für Onkologie* 2009;41(3): 119-25.
32. Son GS, Ryu WS, Kim HY, Woo SU, Park KH, Bae JW. Immunologic response to mistletoe extract (Viscum album L.) after conventional treatment in patients with operable breast cancer. *Journal of Breast Cancer* 2010;13(1): 14-8.
33. Steele M, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Adverse drug reactions and expected effects to therapy with subcutaneous mistletoe extracts (Viscum album L.) in cancer patients. *Evidence-Based Complementary and Alternative Medicine* 2014; Article ID 724258: 11 pages.

34. Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Safety of Intravenous Application of Mistletoe (*Viscum album* L.) Preparations in Oncology: An Observational Study. *EvidenceBased Complementary and Alternative Medicine* 2014; Article ID 236310: 10 pages.
35. Steele ML, Axtner J, Happe A, Kröz M, Matthes H, Schad F. Use and Safety of Intratumoral Application of European Mistletoe (*Viscum album* L) Preparations in Oncology. *Integrative cancer therapies* 2014, 9 pages.
- 36.
37. Stumpf C, Rieger S, Schietzel M. Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Mammakarzinom. *Deutsche Zeitschrift für Onkologie* 2005;37(3): 106- 13.
38. Thronicke, A.; Grabowski, P.; Roos, J.; Wüstefeld, H.; Grah, C.; Johnson, S.; Schad, F. Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW). *Int. J. Mol. Sci.* **2025**, *26*, 3669. <https://doi.org/10.3390/ijms26083669>
39. Tröger W. Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy. A prospective randomized open label pilot study. *Phytomedicine* 2007;14(Suppl VII): 36.
40. Tröger W, Matijasevic M, Zdrle Z, Tisma N, Jezdic S. Additional therapy with mistletoe extracts in breast cancer patients receiving chemotherapy – a prospective randomized open label pilot study. In: Scheer R et al., editors. *Die Mistel in der Tumorthherapie 2*. Essen: KVC Verlag; 2009. S. 509-21.
41. Tröger W, Zdrle Z, Tisma N, Matijasevic M. Additional therapy with mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: an open randomized clinical pilot trial. *Evidence-Based Complementary and Alternative Medicine* 2014; Article ID 430518: 9 pages.
42. Tröger W, Zdrle Z, Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit *Viscum album* (L.) Extrakt. *Deutsche Zeitschrift für Onkologie* 2016;48: 105-110.
43. Tröger W, Zdrle Z Adjuvant therapy of early breast cancer: mistletoe (Helixor) during chemotherapy? Results of a randomized clinical trial with 5-year-follow-up. *Der Merkurstab* 2018; 71(2), 151.